StockIceMan's Weekly Stock Pick
Week of
June 11, 2007
| Stock: |
Encysive Pharmaceuticals,
Inc. |
|
|
| Ticker Symbol: |
ENCY - Nasdaq - Basic Metals -
Biotechnology |
|
|
| Buy: |
4.00 to 4.25 |
|
|
| Sell: |
7.00 |
|
|
|
Info: |
Encysive Pharmaceuticals
Inc., a biopharmaceutical company, engages in
the discovery, development, and
commercialization of novel synthetic small
molecule compounds for the treatment of various
cardiovascular, vascular, and related
inflammatory diseases. It offers Argatroban, a
synthetic direct thrombin inhibitor, for the
treatment of heparin-induced thrombocytopenia in
the United States and Canada; and Thelin (sitaxsentan
sodium), an endothelin receptor antagonist, for
the treatment of pulmonary arterial hypertension
in the European Union and Australia. It also has
three additional compounds in clinical
development, including TBC3711,
second-generation endothelin receptor
antagonist; TBC4746, an oral VLA-4 antagonist;
and bimosiamose, a selectin antagonist. In
addition, the company provides other research
and development programs for various
cardiovascular and inflammatory diseases.
Encysive Pharmaceuticals has collaboration and
licensing agreements with Mitsubishi Pharma
Corporation; GlaxoSmithKline plc; Schering
Corporation; Schering-Plough, Ltd.; and Revotar
Biopharmaceuticals, AG. The company was founded
in 1989. It was formerly known as Texas
Biotechnology Corporation and changed its name
to Encysive Pharmaceuticals, Inc. in 2003.
Encysive Pharmaceuticals is headquartered in
Houston, Texas. |
|
|
| Financial Info: |
For the three months
3/31/2007, revenues rose 52% to $5.4 million.
Net loss from continuing operations before
accounting change fell 1% to $29.9 million |
|
|
| Key Ratios: |
Current
Ratio: 3.324, Total Debt/Equity: N/A, Trailing
P/E: N/A, Forward P/E: N/A, Price/Book:
N/A, Price/Sales: 14.51 |
|
|
| Share Info: |
There are 70.16
million shares outstanding with 68.96
million shares in the trading
float. Institutions own
approximately 43.10% of the shares outstanding.
There have been no insider purchases or sales
in the last six months.
Real-Time SEC
Filings
As of 5/10/2007, there were 9.78 million shares short.
Net Institutional Buying: 3.106 million shares prior to latest
quarter. |
|
|
| Articles: |
Encysive Invades Canada
Encysive receives approval
for Thelin use in Canada |
|
